|
Oct 7
|
ONCY Stock Up on Regulatory Update From Breast Cancer Program
|
|
Oct 7
|
Oncolytics targets accelerated approval for oncolytic virus therapy
|
|
Oct 4
|
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
|
|
Aug 2
|
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
|
|
Aug 1
|
Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
|
|
Jul 24
|
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
|
|
Jun 27
|
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
|
|
Jun 27
|
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
|
|
Jun 24
|
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
|
|
Jun 21
|
Oncolytics doses first subject in pancreatic cancer trial
|
|
Jun 20
|
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
|
|
Jan 9
|
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
|
|
Dec 7
|
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
|
|
Nov 5
|
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
|
|
Nov 3
|
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
|
|
Sep 8
|
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
|
|
Sep 7
|
Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering
|
|
Sep 6
|
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Jun 22
|
Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial
|